The market experienced a wild ride in 2022, making investors hesitant to invest in the stock market. However, the S&P 500 appears to have turned the corner this year, rising 17% so far.

In this recovering market, growth stocks that are still undervalued are a good option for risk-averse investors. CRISPR Therapeutics (NASDAQ: CRSP) is a gene-editing biotech company. Let's take a look at why it's not too late to add this stock to your portfolio. 

Image source: Getty Images.

Continue reading

Source Fool.com